Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Pulmonology (COPD-Chronic Obstructive Pulmonary Disorder), Emphysema
Apogee Therapeutics, Inc. (NASDAQ: APGE)*

Organization & Developments: Apogee Therapeutics

Parents

*Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications.
*Biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications.
2024: Apogee Therapeutics Announces First Participants Dosed in
2024: Apogee Therapeutics Earnings Preview: APG777's Potential In Atopic Dermatitis_seekingalpha.com
2024: Apogee Therapeutics: Success In Phase 1 Bodes Well For Continued APG777 Advancement
2024: Apogee Therapeutics' Innovative Leap In Atopic Dermatitis Management
2024: Here's Why We're Not Too Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn Situation
2025: Apogee Therapeutics: APG808 Asthma Treatment May Overtake Dupixent In IL-4Rα Class
2025: Apogee Therapeutics: No Clinical Efficacy Data, Strong Competition, High Market Cap